Search
OS Therapies Inc
OSTXAdd to Watchlist
1.545USD
+0.025+1.64%
Close 07-27 16:00（ET）Quotes delayed by 15 min
60.68MMarket Cap
LossP/E TTM
More Details of OS Therapies Inc Company
OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
OS Therapies Inc Info
Ticker SymbolOSTX
Company nameOS Therapies Inc
IPO dateAug 01, 2024
CEORomness (Paul A)
Number of employees4
Security typeOrdinary Share
Fiscal year-endAug 01
Address15825 Shady Grove Road
CityROCKVILLE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code20850
Phone14102977793
Websitehttps://ostherapies.com/
Ticker SymbolOSTX
IPO dateAug 01, 2024
CEORomness (Paul A)
Company Executives of OS Therapies Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Ciccio
Mr. John Ciccio
Independent Director
Independent Director
237.92K
--
Dr. Robert G. Petit, Ph.D.
Dr. Robert G. Petit, Ph.D.
Chief Medical Officer, Chief Scientific Officer
Chief Medical Officer, Chief Scientific Officer
200.00K
--
Christopher p Acevedo ,
Christopher p Acevedo ,
Chief Financial Officer
Chief Financial Officer
109.38K
--
Mr. Paul A. Romness
Mr. Paul A. Romness
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Dr. Theodore F. Search, Pharm.D.
Dr. Theodore F. Search, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Avril Mckean Dieser, J.D.
Ms. Avril Mckean Dieser, J.D.
Independent Director
Independent Director
--
--
Mr. Olivier R. Jarry
Mr. Olivier R. Jarry
Independent Director
Independent Director
--
--
Mr. Karim Galzahr
Mr. Karim Galzahr
Director
Director
--
--
Mr. Gerald E. Commissiong
Mr. Gerald E. Commissiong
Chief Business Officer
Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Ciccio
Mr. John Ciccio
Independent Director
Independent Director
237.92K
--
Dr. Robert G. Petit, Ph.D.
Dr. Robert G. Petit, Ph.D.
Chief Medical Officer, Chief Scientific Officer
Chief Medical Officer, Chief Scientific Officer
200.00K
--
Christopher p Acevedo ,
Christopher p Acevedo ,
Chief Financial Officer
Chief Financial Officer
109.38K
--
Mr. Paul A. Romness
Mr. Paul A. Romness
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Dr. Theodore F. Search, Pharm.D.
Dr. Theodore F. Search, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Avril Mckean Dieser, J.D.
Ms. Avril Mckean Dieser, J.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of OS Therapies Inc?
The top five shareholders of OS Therapies Inc are: Mr. John Ciccio
How many institutions hold shares of OS Therapies Inc (OSTX)?
As of 2026Q1, 41 institutions hold shares of OS Therapies Inc, with a combined market value of approximately 2.99M, accounting for 7.12% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1311440.00.